Get to know PIQRAY

The first and only treatment with fulvestrant specifically for postmenopausal women, and men, with a PIK3CA mutation in HR+, HER2- metastatic breast cancer whose disease has progressed on or after endocrine (hormone) therapy.

Important Safety Information:

Do not take PIQRAY® (alpelisib) tablets if you have had a severe allergic reaction to PIQRAY or are allergic to any of the ingredients in PIQRAY.

 

PIQRAY may cause serious side effects, i...

See More
Approved Use:

PIQRAY is a prescription medicine used in combination with the medicine fulvestrant to treat women who have gone through menopause, and men:

  • who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer or breast cancer that ha...
See More
PIK3CA MUTATIONS IN MBC

Testing for PIK3CA Mutations

Your PIK3CA mutation status could inform treatment decisions. Ask your doctor about FDA-approved genomic tests for the detection of PIK3CA mutations. 

LEARN MORE
HOW PIQRAY MAY HELP

Treatment With PIQRAY

Learn more about proven results with PIQRAY + fulvestrant in HR+, HER2- mBC with a PIK3CA mutation.

SEE RESULTS